Library

X
feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • 1995-1999  (2)
  • 1,2-dimethyl-6,7-dihydroxyisoquinolinium ion  (1)
  • Accelerated proliferation  (1)
  • 1
    Electronic Resource
    Electronic Resource
    Cytotoxicity of endogenous isoquinolines to human dopaminergic neuroblastoma SH-SY5Y cells (1997)
    Springer
    Journal of neural transmission 104 (1997), S. 59-66 
    Details
    ISSN: 1435-1463
    Keywords: Cytotoxicity ; isoquinolines ; N-methylsalsolinol ; 1,2-dimethyl-6,7-dihydroxyisoquinolinium ion ; neuroblastoma SH-SY5Y cells
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary Endogenous isoquinolines with and without catechol structure have been proposed to be neurotoxins specific for dopamine neurons. In this paper they were examined for the cytotoxicity of human dopaminergic neuroblastoma SH-SY5Y cells. The cytotoxicity was quantitatively determined using Alamar Blue assay, by which the reduction-oxidation potency in the living cells can be measured spectrometrically. 1,2-Dimethyl-6,7-dihydroxyisoquinolinium ion [1,2-DMDHIQ+], an oxidation product of a parkinsonism-inducing isoquinoline, 1(R),2(N)-dimethyl-6,7-dihydroxy-1,2,3,4-tetrahyroisoquinoline [N-methyl-(R)salsolinol, NM(R)Sal] was found to be the most potent toxin among isoquinolines examined. In general, catechol isoquinolines were more toxic than isoquinolines without catechol structure. With and without catechol structure, the oxidized isoquinolinium ion having methyl groups at C-1 and N-2 positions proved to be more cytotoxic than the simple isoquinolines. The involvement of 1,2-DMDHIQ+ to the neurotoxicity of NM(R)Sal was suggested and discussed.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF01271294
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 2
    Electronic Resource
    Electronic Resource
    A phase II study of cisplatin, oral administration of etoposide, OK-432 and radiation therapy for inoperable stage III non-small cell lung cancer (1998)
    Springer
    International journal of clinical oncology 3 (1998), S. 365-369 
    Details
    ISSN: 1437-7772
    Keywords: Stage III non-small cell lung cancer ; CDDP ; VP-16 ; Conventional radiotherapy ; Concurrent chemoand radiotherapy ; Accelerated proliferation
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract Background. This study was designed to evaluate the feasibility and efficiency of giving cisplatin, etoposide, and OK432 concurrently with conventional radiotherapy (RTx) for patient's with inoperable stage III, based on the TNM classification according to the International Union against Cancer staging system for lung cancer (1987) non-small cell lung cancer (NSCLC). Methods. From January 1992 to December 1994,31 patients with cytologically or histologically confirmed stage III NSCLC were treated with RTx, to a total dose of 56–64 Gy, with concurrent daily oral administration of etoposide (25mg) and cisplatin (20mg) for 5 days during the third or fourth week from the start of RTx. The subcutaneous injection of 1 or 2 KE of OK-432, three times a week, for the duration of radiotherapy also started from the beginning of RTx. Results. The number of eligible patients was 29 (26 men and 3 women). Their mean age was 66 years (range, 55–77 years). Six patients had an Eastern Cooperative Oncology Group performance status (PS) of 0; 15, 1; 8; 2. Three were stage IIIA, and 26, stage ITIB. Histologically, 2 had adenocarcinoma, 23, squamous cell carcinoma, and 4, large cell carcinoma. In 27 of the 29 patients, the RTx schedule was completed. There were no treatment-related deaths. Grade 4 toxicity (according to World Health Organisation criteria) leukopenia (700/μl was observed in 1 patient. The response rate was 79% and the median survival was 17 months. Survival rates at 1, 2 and 3 years were 62%, 31%, and 21%, respectively. The local failure rate was 51%. Conclusion. The combination of cisplatin, etoposide, and K-432, given concurrently with conventional RTx is feasible and effective for inoperable stage III NSCLC.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF00539214
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...